Fundación Teófilo Hernando, Spain   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Madrid Spain (1960)

Organization Overview

First Clinical Trial
2010
NCT05029297
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Fundación Teófilo Hernando, Spain

Active Ingredients

Drugs in Phase 3 Trials (1)

capsaicin (qutenza) (1 trial)

Drugs in Phase 2 Trials (1)

ponatinib (iclusig) (1 trial)

Drugs in Phase 1 Trials (1)

contraloid (2 trials)

Drugs in Other Trials (1)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4